triiodothyronine (T3) 0.94 (0.80-2.00) ng/mL; thyroxine (T4) 6.4 (5.1-14.1) mg/dL; free T3 (FT3) 3.95 (3.10-6.80) pmol/L; free T4 (FT4) 15.57 (12.00-22.00) pmol/L; thyroidstimulating hormone (TSH) 2. 56 (0.27-4.20) mU/L; thyroid peroxidase antibody (TPOAb) 8.2 (0-34.0) IU/mL; thyroglobulin antibody (TgAb) <10 ( 115) IU/mL; total bilirubin (T-BIL) 21.5 (5.0-22.0) mmol/L; direct bilirubin (D-BIL) 6.3 (0-10.2) mmol/L; alanine transaminase (ALT) 27.5 (7.0-40.0) U/L; aspartate transaminase (AST) 22.7 (13.0-35.0) U/L; and alkaline phosphatase (ALP), 48.9 (35.0-100.0) U/L. Hepatitis C antibody, hepatitis B surface antigen, and hepatitis B core antibody immunoglobulin M tested negative.
To the Editor: On March 9, 2018, a 31-year-old woman presented with liver dysfunction after thyroid cancer surgery. She was physically healthy; had no chronic diseases, such as hypertension and diabetes; had no history of infectious diseases, such as hepatitis and tuberculosis; had no history of drugs, food allergies, smoking, and alcohol consumption; and presented no obvious complaints during the disease course. B-ultrasound in the physical examination 3 years prior showed "left thyroid-occupying position." On February 5, 2018, she had undergone surgery at our hospital. Laboratory findings on February 6, 2018 revealed white blood cells (WBCs) 9.06 Â 10 9 /L (3.50-9.50 Â 10 9 /L); neutrophils (NEs) 5.66 Â 10 9 /L (1.80-6.30 Â 10 9 /L); triiodothyronine (T3) 0.94 (0.80-2.00) ng/mL; thyroxine (T4) 6.4 (5.1-14.1) mg/dL; free T3 (FT3) 3.95 (3.10-6.80) pmol/L; free T4 (FT4) 15.57 (12.00-22.00) pmol/L; thyroidstimulating hormone (TSH On February 7, 2018, intra-operative pathology during left thyroidectomy indicated micro-papillary carcinoma. On February 11, 2018, she was discharged and prescribed levothyroxine tablets A (LTA; Merck KGaA, Darmstadt, Germany) 100 mg and calcium carbonate D3 tablets (CC-D3; Pfizer, China) 600 mg once daily.
On March 9, 2018, outpatient review laboratory findings revealed T3 1.11 ng/mL; T4 8.7 mg/dL; FT3 5.50 pmol/L; FT4 20.13 pmol/L; TSH 0.035 mU/L; thyroid-stimulating receptor antibody <0.3 IU/L; T-BIL 16.2 mmol/L; D-BIL 4.10 mmol/L; ALT 325.2 U/L; AST 144.9 U/L; and ALP 60.6 U/L. Anti-nuclear antibody (ANA), anti-mitochondrial antibody M2 sub-type (AMA-M2), anti-smooth muscle antibody (ASMA), anti-liver kidney microsomal antibody (LKM-1), anti-soluble liver antigen/liver-pancreatic antigen antibody (SLA/LP), and hepatocyte solute antigen (LC-1) tested negative. We suspected liver injury induced by LTA. The R value [R = (ALT measured_value /ALT normal_upper_limit )/ (ALP measured_value /ALT normal_upper_limit )] was 13.42. [1] Therefore, the admission diagnosis was drug-induced liver injury (hepatocyte injury type, acute, Roussel Uclaf causal relationship assessment method [RUCAM] 6 points, severity grade 1) and thyroid papillary cancer.
Admission examinations revealed body temperature 36.4°C; pulse 74 times/min; and blood pressure 120/65 mmHg. No yellow staining of the skin and mucous membranes and no liver area pain were noted. After admission, LTA was reduced to 75 mg once daily, and she continued to take CC-D3 tablets 600 mg once daily. Considering her hepatocyte injury type, magnesium isoglycyrrhizinate injection 100 mg with reduced glutathione for injection 2.4 g were intravenously dripped once daily for liver protection. Laboratory examinations on March 12, 2018 revealed the following: LTA was discontinued and switched to levothyroxine tablets B 75 mg (LTB; Berlin Chemie AG, Germany) once daily. GAD capsules, PPC capsules, and CC-D3 tablets were continued. On April 6, 2018, she presented with T-BIL 10.70 mmol/L; D-BIL 3.00 mmol/L. LTB was increased to 87.5 mg once daily, GAD capsules were reduced to 50 mg 3 times/day, PPC capsules were reduced to 228 mg 3 times/ day, and CC-D3 tablets were continued. On May 10, 2018, she presented with T-BIL 15.30 mmol/L; D-BIL 3.90 mmol. LTB was increased to 87.5 mg and 100 mg, once daily alternately; GAD capsules and PPC capsules were discontinued. On June 19, 2018, she presented with T-BIL 16.00 mmol/L; D-BIL 4.60 mmol/L. LTB was increased to 100 mg once daily. On August 7, 2018, she presented with T-BIL 13.00 mmol/L; D-BIL 3.30 mmol/L. Abdominal Bultrasound showed no obvious abnormalities.
The patient's liver function indicators before taking LTA were within normal ranges before treatment and were impaired after 26 days of treatment; transaminases decreased after 16 days of reduction and liver protection treatments. However, her liver function did not return to the pre-dose level, and we switched LTA to LTB. Transaminases decreased further after 12 days. She had no obvious abdominal B-ultrasound or autoimmune liver group abnormalities, liver dysfunction caused by liver parenchymal lesions were excluded, and TPOAb and TgAb tested negative, which could eliminate transient liver dysfunction caused by autoimmune thyroiditis. Since the main component of LTA and LTB is levothyroxine, their differences arise from their different additives. LTA additives are corn starch, gelatin, lactose, and stearic acid magnesium, while those of LTB are calcium bicarbonate, dextrin, long-chain glycerate, sodium carboxymethyl starch, and microcrystalline cellulose. Corn starch, gelatin, lactose, and stearic acid magnesium may have caused liver injury after considering RUCAM evaluation. [1] In 1986, Shibata et al [2] reported that triiodothyronine (4 months) and levothyroxine (4 days) caused liver damage in a patient; Ohmori et al [3] and Kawakami et al [4] reported a case of liver injury caused by levothyroxine (27 days and 2 months, respectively). The mechanism may involve levothyroxine being a hapten-carrier protein complex where in the presenting cells are incorporated and digested. Some complexes are recognized by T lymphocytes, eventually causing liver damage. Recently, liver damage caused by levothyroxine tablets containing different additives has been reported. Per Toki et al, [5] liver damage may be caused by levothyroxine tablets containing Fe 2 O 3 .
In summary, the patient developed liver damage after taking LTA. Liver function gradually returned to normal after liver protection and switching to LTB. Liver dysfunction caused by additives is rare. We suggested that patients with adverse reactions to additives should avoid taking subsequent additive-containing treatments.
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